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Abstract
Although there have been signiﬁcant advances in the treatment of visceral leishmaniasis (VL), there remain challenges to ensure that
treatments effective in India are also effective in other regions of the world and to identify treatment for post kala-azar dermal leish-
maniasis as well as the opportunity to develop a safe oral short-course treatment. At the same time, there have been few advances for
the treatment of simple or complex forms of cutaneous leishmaniasis (CL), other than topical paromomycin formulations. The main
challenge for CL is to ensure that this disease is on the research and development agenda, so that new drugs are evaluated or com-
pounds are screened in appropriate models, and that the standardization of quality of clinical trials is guaranteed. Problems also remain
in the treatment of HIV/leishmaniasis co-infected patients. We are some way from having the ideal treatments for VL and CL and drug
research and development for these diseases must remain focused.
Keywords: Cutaneous leishmaniasis, drug sensitivity, HIV co-infection, standardization, visceral leishmaniasis
Article published online: 12 July 2011
Clin Microbiol Infect 2011; 17: 1478–1483
Corresponding author: S. L. Croft, Faculty of Infectious and Tropi-
cal Diseases, London School of Hygiene & Tropical Medicine, London
WC1E 7HT, UK
E-mail: simon.croft@lshtm.ac.uk
Introduction
There have been signiﬁcant differences in progress and
approaches to drug development for visceral leishmaniasis
(VL) and cutaneous leishmaniasis (CL); these two manifesta-
tions will therefore be discussed separately. There are sev-
eral underlying aspects of the biology of Leishmania parasites
that affect drug development. For both forms of the disease
this includes (i) the intracellular location of the target form
of the pathogen, the amastigote, in the low pH phagolysoso-
mal compartment of different macrophage populations and
(ii) the varying sensitivities of strains and species com-
pounded by their inter-relationship with the host immune
response, which under some circumstances renders drugs
ineffective. Where there might be differences in drug devel-
opment between VL and CL relates mainly to the require-
ments of the different pharmacokinetic properties of
compounds that distribute to the viscera (liver, spleen, bone
marrow in VL) or skin (in CL) and to the pharmaceutical
formulation of drugs that aid that distribution. Other more
subtle differences relating to immunological responses
include approaches to accelerate self-cure, especially in CL.
Visceral Leishmaniasis
Current status
As VL, caused by L. donovani (in Asia and Africa) and L. infan-
tum (in southern Europe, as wells as South America where it
used to be referred to as L. chagasi), is potentially fatal, it is
included as a target disease by players in drug research and
development (R&D), for example product development part-
nerships such as DNDi (Drugs for Neglected Diseases initia-
tive), iOWH (Institute for One World Health), CPDD
(Consortium for Parasitic Drug Development), funders such
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as the Bill and Melinda Gates Foundation, and the pharma-
ceutical industry, for example Novartis.
Pentavalent antimonials, the standards drugs for 60 years,
are now almost obsolete in the key endemic area in Bihar
state, India because of parasite resistance [1], but are still
useful in the rest of the world as sodium stibogluconate
(Pentostam), meglumine antimoniate (Glucantime) [2] or a
generic brand of sodium stibogluconate at reduced cost [3]
(Table 1). Amphotericin B, normally considered a second-line
drug, has been the ﬁrst line in Bihar following the loss of
effectiveness of antimonial drugs. Although a number of
amphotericin B lipid formulations, developed during the
1980s for treatment of systemic mycoses in immunocompro-
mised patients, have proved effective in the treatment of VL,
only one of these, the liposomal formulation AmBisome,
has become a standard treatment. It is registered for the
treatment of VL in various countries and its use is recom-
mended by a WHO working group [4]. Recently, a single-
course therapy of 10 mg/kg has been shown to cure 95% of
patients in India [5]. The signiﬁcant reduction in price negoti-
ated by WHO with the producers (Gilead, Foster City, CA),
currently $18/50 mg ampoule) is an important component in
the impact of this drug. However, AmBisome remains an
expensive treatment as several ampoules will be required
even for single-course treatment [6], administration is intra-
venous and there are adverse events [5], and temperature
stability (manufacturer guarantee 25C) is an issue. A paren-
teral formulation of the aminoglycoside paromomycin (ami-
nosidine, monomycin), was ﬁrst shown to have a curative
effect in VL in the 1980s and moved slowly through clinical
trials with WHO/Special Programme for Research & Training
in Tropical Diseases (TDR) in the 1990s and iOWH in the
2000s. An extensive study by iOWH in India showed 94%
efﬁcacy (15 mg/kg for 21 days, intramuscularly) in phase III
clinical trials in India [7], leading to registration for VL in
India in 2006. The anti-leishmanial activity of the phospholipid
derivative, miltefosine was ﬁrst identiﬁed in the 1980s [8];
the drug was registered as the ﬁrst oral treatment for treat-
ment of VL in India in 2002 following clinical trials by WHO/
TDR and Zentaris (Frankfurt, Germany) that showed 94%
efﬁcacy in adults and children [9]. It was also the ﬁrst anti-
leishmanial to undergo phase IV studies [10], and was incor-
porated into the VL elimination programme for the sub-con-
tinent. Issues around the drug have been (i) potential
teratogenicity, requiring women of child-bearing age to take
contraception, which they have to take for up to 3 months
after treatment because of the long residence time of the
drug in the patient organism, and (ii) the 28-day oral treat-
ment, which leads to poor compliance. Drug combinations
have proved to be a successful strategy to shorten the
course of therapy, reduce toxicities through lower dosage
and reduce the selection of resistant mutations for several
infectious diseases, most notably malaria and tuberculosis
[11]. Although the opportunity for co-formulation, with
improved compliance, is not available for VL, a strategy of
co-administration (either concomitant or sequential) of avail-
able anti-leishmanial drugs has been pursued by DNDi and
others following on from experimental studies [12], pre-clini-
cal toxicokinetic studies (DNDi, unpublished) and a pilot
clinical study [13] to provide efﬁcacy and safety data. A
phase III study on three co-administration regimens showed
that for Indian VL: (i) single-dose intravenous AmBi-
TABLE 1. Drugs in use for treatment of leishmaniasis, alone or co-administered
Drug Properties and administration Comment
Sodium stibogluconate
(Pentostam, SSG) and
meglumine antimoniate
(Glucantime)
Organo-metal complexes in polymeric forms.
Pentostam contains around 33% and
Glucantime around 28% pentavalent antimony,
intravenous or intramuscular
For VL and CL. There is extensive drug resistance
in Bihar India. Variable response in different
species that cause CL.
Generic sodium stibogluconate (SSG) has made
treatment cheaper.
Amphotericin B
(Fungizone)
Polyene antibiotic, fermentation product of
Streptomyces nodus, intravenous
For VL, CL and complex forms of CL, e.g. mucocutaneous
leishmaniasis. Has been ﬁrst-line drug for VL in India where
there is antimonial resistance.
Liposomal amphotericin B
(AmBisome)
Unilamellar liposome, intravenous Proved to be most effective lipid formulation for VL and
available at $18/50 mg ampoule via WHO. Also used for
complex forms, such as PKDL and mucocutaneous leishmaniasis
Miltefosine Hexadecylphosphocholine, oral First oral drug for VL. Also effective against some species that cause CL.
Contraindicated in pregnancy as found to be teratogenic in rats.
Paromomycin Aminoglycoside (also known as aminosidine or monomycin),
fermentation product of Streptomyces rimosus. Supplied as
sulphate. Intramuscular for VL and topical for CL.
Registered for VL in India, completed phase III trials for VL in
East Africa where less effective in Sudan. Topical formulation
(12%) with methyl benzylmethonium chloride available for CL.
Topical with gentamicin and surfactants in Phase III trial.
Amphotericin B
formulations
Lipidic formulations, intravenous Other lipid formulations, including Abelcet, Amphocil, Amphomul and
multi-lamellar liposomes have been in clinical studies,
mainly for VL.
Pentamidine Diamidine, as isethionate salt, intramuscular For speciﬁc forms of CL in South America only.
CL, cutaneous leishmaniasis; PKDL, post kala-azar dermal leishmaniasis; VL, visceral leishmaniasis.
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some + sequential 7 days oral miltefosine, (ii) single-dose
intravenous AmBisome + sequential 10 days intramuscular
paromomycin, and (iii) concomitant 10 days oral miltefo-
sine + 10 days intramuscular paromomycin achieved a 98%
cure rate [14]. The essential point of the study is the greatly
reduced treatment time—from 30 days to potentially
8 days—important for both patient treatment and VL con-
trol. The advantages of this approach have been recently
reviewed in relation to criteria for use [11] and cost [6].
The Indian studies did not include pentavalent antimonials
within the co-administrations because of the extensive drug
resistance in that region.
Challenges and opportunities
It is a major challenge to develop any new drug for the
treatment of VL. An additional issue to be tackled is the
regional, and perhaps strain, differences in response rates to
drugs. A study over 10 years ago suggested that AmBisome
was most effective in treating VL patients in India, less so in
East Africa (L. donovani), and even less so against L. infantum
(L. chagasi) in South America [15]. Clinical studies to conﬁrm
the worldwide efﬁcacy of AmBisome for VL are required
and are underway in East Africa (http://www.dndi.org) and
Brazil. Clinical trials with paromomycin in East Africa using
the same 15-mg/kg regimen for 21 days that was successful
in India, showed much lower efﬁcacy, particularly in Sudan
where the cure rate was <50%. Even the increased dose of
20 mg/kg for 21 days gave only an 85% cure rate, insufﬁcient
for consideration as a monotherapy [16]. The reasons for
these differences are not understood.
The dermal manifestation, post kala-azar dermal leishmani-
asis (PKDL), which appears weeks to years after the end of
treatment of visceral disease, remains poorly understood and
whether this phenomenon is related to speciﬁc types of drug
treatment is not clear [17]. There is no recommended treat-
ment for PKDL and current practice is based upon long
courses of antimonial treatment; small studies with miltefo-
sine and AmBisome have been described [2,18]. The poten-
tial of an immunotherapeutic approach, using antimony plus
vaccine plus bacillus Calmette–Gue´rin (BCG), showed higher
cure rate than drug alone [19] and there are further oppor-
tunities for research in this area [20].
At the same time there are opportunities for improved
use of drugs in treatment and control. For miltefosine, there
is need for care in the use of this drug as both the 28-day
course of oral therapy, with issues of compliance, and the
long drug half-life favour the selection of resistant forms and
use of a direct observed therapy system, as used for tuber-
culosis treatment, could be implemented [21,22]. For most
drugs that have been recently introduced there is limited
clinical pharmacokinetic and pharmacokinetic/pharmacody-
namic information. However, an exemplary study was com-
pleted on sitamaquine, an oral 8-aminoquinoline, that had
undergone extensive phase II trials in India and East Africa
but is no longer in development (Glaxo Smith Kline, personal
communication) because of <90% cure rates [23,24], which
should provide a guide for studies on future anti-leishmanial
drugs [25]. The importance of phase IV studies in the imple-
mentation of new drugs should not be underestimated and
the information from trials in India on miltefosine [10] and
paromomycin (a phase IV trial in 2008–2009 showed a cure
rate of 94.2% at 6 months post-treatment, P. Desjeux, per-
sonal communication) helps to guide use. The next step in
assessing the beneﬁt and safety of new anti-leishmanials,
pharmacovigilance, has been advocated and the steps
required have been outlined [26].
Other challenges and opportunities are part of the drug
R&D programmes, which given the recent progress in treat-
ment with AmBisome and co-administrations, underline the
need for a safe oral drug with >95% efﬁcacy following a 10–
14-day course.
Cutaneous Leishmaniasis
There are a limited number of proven treatment options for
CL (Table 1). The issues of species variation, 15 Leishmania
species can cause CL, and pharmacokinetics are major prob-
lems. Pentavalent antimonials have proved inconsistent in
their effectiveness across the different Leishmania species,
and pentamidine and amphotericin B are limited to speciﬁc
types of CL [2]. Paromomycin has been tried in different
topical formulations with variable clinical results [27,28]. A
recent formulation of 12% paromomycin, containing also gen-
tamicin and surfactants, showed efﬁcacy in L. major CL in
Tunisia [29], but the trial again exempliﬁed the problems of
design in a self-curing disease [30]. Oral miltefosine also has
some variable, species-dependent effectiveness against CL
[31,32]; it is registered for this indication in Colombia. A ret-
rospective study also indicated that liposomal amphotericin B
could have some use in the treatment of CL [33].
Two recent Cochrane analyses of clinical trials of CL in
the New World (the Americas) and the Old World (every-
where else) concluded that most clinical studies were not
worthy of inclusion in the analysis because they did not meet
standards of randomized placebo-controlled trials. Of the
Old World trials that were included, there was some evi-
dence of the activity of antifungal azoles, ﬂuconazole for
L. major [34,35] and itraconazole for L. tropica [34], whereas
in the New World, in addition to antimonials, miltefosine
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and ketoconazole, and oral allopurinol were active in a lim-
ited number of trials [36]. One of the trials included in the
Cochrane analyses involved the anti-inﬂammatory drug pent-
oxyphylline, as adjunct therapy. As one of the aims of treat-
ment of CL is to accelerate self-cure [27], approaches
including immunomodulators as adjunct therapies are impor-
tant and have been trialled for many years, including BCG
and trehalose dimycolate to small molecules such as the anti-
viral Toll-like receptor 7 agonist imiquimod. Studies on CL
patients in Peru showed 75% cure for imiquimod plus anti-
monials compared with 58% for antimonials alone [37].
There have also been extensive studies using BCG with pen-
tavalent antimonials in Venezuela [38].
Challenges and opportunities
As there are questions over the reliability of data on treat-
ments for CL, and concerns about the paucity of randomized
placebo-controlled trials [39,40] recent efforts to establish a
standardized protocol [41] are important. Issues regarding
start points (recruitment of patients with new or old lesions),
and end points (resolution of nodules and lesion or complete
re-epithelialization of ulcerated lesions), have to be resolved.
The analysis and proposals essentially refer to simple cutane-
ous leishmaniasis. More complex mucocutaneous and diffuse
forms of the disease, probably 5% of all cases, where there
are metastatic sites of infection, remain a major challenge.
There are no clear recommended forms of treatment and
topical approaches would be inappropriate. Long courses of
antimonials are used for treatment of mucocutaneous disease
caused by L. braziliensis [2] and AmBisome and miltefosine
have proved successful in some limited trials [42,43].
There are opportunities in drug R&D. In addition to
exploiting the potential of new drugs being developed for
VL, there are examples of some success with therapeutic
switching and rational pharmaceutical design of topical for-
mulations. In the former category, a recently developed anti-
fungal triazole, posaconazole, has shown activity against CL
in experimental models [44] and also in one patient [45],
supporting further investigation of this class of compounds.
In the latter category, the topical approach offers advantages
for simple CL (minimal systemic exposure, lesion protected
from super-infections) but has limitations for complex CL
(multiple lesions, lesions close to eye, potentially metastasiz-
ing forms); systemic treatments have disadvantages (high sys-
temic exposure versus low skin concentrations). A recent
example of the rational pharmaceutical approach is the
performance of studies with the anti-protozoal agent, bu-
parvaquone, where topical formulations that can deliver
drugs to the infected dermal layer in rodent models of infec-
tion have been designed [46,47].
Cutaneous leishmaniasis is not part of the R&D agenda
of many foundations, partnerships or the industrial sector.
The impact of this neglected disease and a road map to
develop improved drugs, diagnostics and immunotherapeu-
tics need to be raised on the international agenda. Some
attempts have been made and target product proﬁles have
been produced for key forms of CL caused by L. tropica and
L. braziliensis [39].
Leishmaniasis Co-infections—Challenges
Co-infections of HIV and Leishmania have been reported for
VL and CL. Since the ﬁrst reported case of HIV–VL in 1985,
35 countries have reported co-infections with increasing
numbers of cases in East Africa; recent reports are 23% of
all VL cases in northeast Ethiopia. A range of treatment regi-
mens with all standard drugs have been described to treat
VL in co-infection cases, with relapse rates of 0–85% (39).
The most recent review by Alvar et al.[48] highlights the
major concerns around the increased risk of developing VL
in HIV co-infected patients, by 320 times in areas of ende-
micity, the reduced likelihood of a therapeutic response and
the greatly increased probability of relapse. Currently there
is no successful current therapy for patients co-infected with
HIV–VL. Countries have different policies; some have
adopted a regimen of treatment with anti-retrovirals fol-
lowed by treatment with anti-leishmanial drugs. Other
countries have adopted a policy of maintenance therapy, for
example in southern Europe, patients move to maintenance
therapy often involving lipid amphotericin B formulations.
This co-infection exempliﬁes the need for effective immune
response and that drugs alone cannot clear parasites com-
pletely without concurrence by the immune system. The
need to raise the importance of HIV–VL on the R&D agenda
is crucial.
Summary
There have been signiﬁcant advances in the treatment of VL
but there have been few for the simple or complex forms
CL, with only topical paromomycin in clinical trial for simple
CL. The situation for HIV co-infected patients remains dire.
Although we now have single-dose AmBisome and short-
course co-administrations for VL, the goal still remains a safe
cheap oral drug requiring a 10–14-day course of treatment;
this goal appears to be distant for both forms of the disease.
However, there is potential for further development of topi-
cal formulations for simple CL. We are some way from hav-
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ing the ideal treatments for VL and CL and drug R&D for
these diseases needs to be kept high on the agenda.
Transparency Declaration
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